First American Trust Fsb Lowers stake in Amgen (AMGN)

Amgen (AMGN) : First American Trust Fsb reduced its stake in Amgen by 22.63% during the most recent quarter end. The investment management company now holds a total of 21,802 shares of Amgen which is valued at $3.4 Million after selling 6,376 shares in Amgen according to a report filed by the company on Apr 5, 2016 with the SEC.Amgen makes up approximately 1.20% of First American Trust Fsb’s portfolio.

Other Hedge Funds, Including , Weaver C. Barksdale Associates reduced its stake in AMGN by selling 33 shares or 0.63% in the most recent quarter. The Hedge Fund company now holds 5,200 shares of AMGN which is valued at $813,228. Amgen makes up approx 0.61% of Weaver C. Barksdale Associates’s portfolio. Pensionfund Sabic sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 21,000 shares of AMGN which is valued $3.3 Million.Lvm Capital Management Ltdmi boosted its stake in AMGN in the latest quarter, The investment management firm added 32,710 additional shares and now holds a total of 68,620 shares of Amgen which is valued at $10.7 Million. Amgen makes up approx 3.42% of Lvm Capital Management Ltdmi’s portfolio. Pensionfund Dsm Netherlands sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 42,000 shares of AMGN which is valued $6.6 Million.

On the company’s financial health, Amgen reported $2.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.29. The company had revenue of $5536.00 million for the quarter, compared to analysts expectations of $5534.94 million. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 EPS.

Investors should note that on Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.Shares were Reiterated by Argus on Feb 8, 2016 to “Buy” and Lowered the Price Target to $ 185 from a previous price target of $202 .Credit Suisse Initiated Amgen on Jan 20, 2016 to “Outperform”, Price Target of the shares are set at $205.

Amgen closed down -0.07 points or -0.04% at $156.39 with 27,32,781 shares getting traded on Monday. Post opening the session at $156.4, the shares hit an intraday low of $155.28 and an intraday high of $157.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.